Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
AssigneeLudwig Institute for Cancer Research
InventorsSophie Lucas, Charles De Smet, Thierry Boon-Falleur
Life of this patent
Estimating the term…
Abstract
The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
Claims32
An isolated nucleic acid molecule which encodes a TRAP having an amino acid sequence of a TRAP encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 9 and SEQ ID NO:
- 18.
An isolated nucleic acid molecule having a nucleotide sequence which encodes a tumor rejection antigen precursor, said isolated nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO:
- 9 or SEQ ID NO:
- 18.
An isolated nucleic acid molecule, the complementary sequence of which hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence which consists of nucleotides 1-2815 of SEQ ID NO:
- 9 with the proviso that the complementary sequence does not hybridize to SEQ ID NO:
- 8 under stringent conditions.
Kit useful in a polymerase chain reaction based assay, comprising an oligonucleotide having a sequence of nucleotides 18-34 of SEQ ID NO:
- 1 and an oligonucleotide having a nucleotide sequence, which is complementary to nucleotides 200-217 of SEQ ID NO:
- 1.
Method for determining expression of a MAGE-C1 gene in a sample, comprising contacting said sample with an oligonucleotide having a sequence consisting of (i) nucleotides 18-34 of SEQ ID NO:
- 1 and (ii) an oligonucleotide having a sequence which is complementary to nucleotides 200-217 of SEQ ID NO:
- 1, under conditions favoring hybridization of the sequences of (i) or (ii) to an MAGE-C1 coding sequence, carrying out polymerase chain reaction and determining expression product to determine presence of an MAGE-C1 coding sequence in said sample.
An isolated nucleic acid molecule, the complementary sequence of which hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth by SEQ ID NO:
- 18 with the proviso that the complementary sequence does not hybridize to SEQ ID NO:
- 8 under stringent conditions.
Method for determining expression of a MAGE-C2 gene in a sample, comprising contacting said sample with (i) an oligonucleotide having a sequence set forth by SEQ ID NO:
- 15 and (ii) an oligonucleotide having a sequence set forth by SEQ ID NO:
- 16, under conditions favoring hybridization of the sequences of (i) or (ii) to an MAGE-C2 coding sequence, carrying out polymerase chain reaction and determining expression product to determine presence of an MAGE-C2 coding sequence in said sample.
A polytope comprising a plurality of tumor rejection antigens derived from MAGE-C1 or MAGE-C2 tumor rejection antigen precursors.
A polytope comprising at least one tumor rejection antigen derived from MAGE-C1 or MAGE-C2 tumor rejection antigen precursor and at least one other tumor rejection antigen.
Dependencies are inferred from the claim text.